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Novel synthetic collagen ﬁbers, poly(PHG) made by polycondensation of Pro-Hyp-Gly, spontaneously
assume polymeric structure with molecular weights greater than 105. Its application for biomateri-
als has been explored, but that for a platelet agonist has not been investigated. Poly(PHG)-induced
platelet aggregation independently of thromboxane A2 and integrin a2b1. Poly(PHG)-induced
tyrosine phosphorylation of glycoprotein VI (GPVI)-related molecules and failed to activate GPVI/
FcRc-deﬁcient platelets. Binding of GPVI to poly(PHG) was conﬁrmed by a surface plasmon
resonance spectroscopy, suggesting that poly(PHG) activates platelets through GPVI. Poly(PHG) is
an useful research tool to investigate GPVI-mediated signals and a substitute for collagen in platelet
functional assays.
 2008 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The interaction between platelets and collagen exposed at sites
of vessel damage plays an important role not only in cessation of
bleeding but also in pathological thrombus formation that is
responsible for stroke and myocardial infarction. The interaction
between collagen receptors in platelets and collagen leads to the
inside-out activation of the integrin aIIbb3 and the release of the
secondary mediators, such as ADP and thromboxane A2 (TXA2),
culminating in platelet aggregation mediated by ﬁbrinogen bind-
ing to aIIbb3 and thrombus formation.
In clinical practice, platelet functional tests are often performed
to evaluate bleeding disorders or to monitor the effect of anti-
platelet drugs. Platelet functions are ordinarily assessed with
platelet aggregometry based upon changes in the optical density
of platelet suspensions when stimulated with platelet activators
(agonists). For this purpose, collagen ﬁbers puriﬁed from animal
tissues are widely used as an agonist. However, collagen prepara-
tions derived from animal tissues have several shortcomings, suchchemical Societies. Published by E
ivation of T cells; SLP-76, SH2
latelet aggregation threshold
e A2.
.as variability in biological activities and susceptibility to contami-
nation by infectious pathogens. Particularly, the former is one of
the largest hindrances to preclude the standardization of platelet
aggregation tests in clinical use.
Platelets are known to have two major receptors for collagen,
the integrin a2b1 and the glycoprotein VI/FcRc-chain complex
(GPVI), as well as with a number of minor receptors of uncertain
signiﬁcance [1]. Since GPVI is the most powerful signaling receptor
among collagen receptors that plays a major role in thrombus for-
mation [1], the GPVI signal transduction pathway has been the tar-
get for extensive investigation. To deﬁne the characteristics of the
GPVI-mediated platelet activation, researchers have convention-
ally used GPVI speciﬁc agonists, collagen-related peptide (CRP;
Gly-Lys (or Cys)-Hyp-(Gly-Pro-Hyp)10-Gly-Lys (or Cys)-Hyp-Gly)
[2,3] and the snake toxin convulxin [4]. However, the experiments
using these agents have often met difﬁculties, since CRP must be
cross-linked in each laboratory, which results in variable activity,
and convulxin easily undergoes inactivation.
Recently, Tanihara and his group developed synthetic collagen
ﬁbers consisting of the Pro-Hyp-Gly sequence by direct polycon-
densation of Pro-Hyp-Gly tripeptides [5]. The synthetic collagen ﬁ-
bers named as poly(PHG) have molecular weights greater than 105
and form triple-helical structure like natural collagen. Similar to
natural collagen, poly(PHG) is a huge polypeptide and spontane-
ously assumes polymeric structure without chemical cross-linking.lsevier B.V. All rights reserved.
82 O. Inoue et al. / FEBS Letters 583 (2009) 81–87Since poly(PHG) has collagen-like structure, but is thermally stable
up to the temperature of 80 C and it contains no pathogen, appli-
cation of poly(PHG) for biomaterials and cosmetics has been exten-
sively investigated [6]. However, whether poly(PHG) can be used
as a platelet agonist has not been elucidated to date.0
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Fig. 2. Poly(PHG) stimulates increase in tyrosine phosphorylation of signaling
molecules downstream of GPVI. Human washed platelets were stimulated with
3 lg/ml of CRP or 0.3 lg/ml of poly(PHG) for 2 min. Immunoprecipitation using
antibodies against Syk, SLP-76, LAT, or PLCc2, or pull down assay using GST-Syk
SH2 were performed as described in Section 2. Whole-cell lysates (A) or precip-
itated proteins (B) were separated by SDS–PAGE, electrotransferred, and Western
blotted by the indicated antibodies.2. Materials and methods
2.1. Materials
Fc Receptor (FcR) c-chain-deﬁcient mice (C57BL/6) were gen-
erous gifts from Dr. Takashi Saito (RIKEN Research Center for Al-
lergy and Immunology, Japan). The recombinant extracellular
domain of human GPVI expressed as a dimeric human immuno-
globulin Fc domain fusion protein (GPVI-hFc2) was kindly do-
nated by Drs. Masaaki Moroi and Yoshiki Miura (Kurume
University, Japan) [7]. Collagen reagent Horm, as native type I ﬁ-
brils from equine tendons, was from Nycomed Pharma (Munich,
Germany). CRP (GKO[GPO]10GKOG; single-letter code, where O
is hydroxyproline) was synthesized by Toray Research Center (To-
kyo, Japan); it was cross-linked with 0.25% glutaraldehyde for 3 h
at 4 C and then dialyzed into phosphate-buffered saline (PBS).
Poly(PHG) was synthesized as described previously [5]. In brief,
Pro-Hyp-Gly (Peptide Institute, Osaka, Japan) was dissolved in
phosphate buffer and mixed with 1-hydroxybenzotriazole and
1-ethyl-3-(3-dimethyl-aminopropyl)-carbodiimide hydrochloride.
After stirring for 2 h at 4 C, and then for 46 h at 20 C, the reac-
tion mixture was dialyzed against water. A glutathione S-transfer-
ase (GST)-fusion protein containing the tandem SH2 domains of
Syk (GST-Syk-SH2) was obtained and expressed as described pre-
viously [8]. The recombinant human immunoglobulin Fc domain
fusion protein (hFc2) was produced as described previously [9].
The following materials were obtained from the indicated suppli-
ers, respectively: phospholipase Cc2 (PLCc2) (Santa Cruz Biotech-
nology, CA); anti-LAT (linker for activation of T cells) antibody,
anti-phosphotyrosine antibody (4G10), and anti-integrin a2 anti-
body (A2-IIE10) (Millipore Corporation, MA, USA); anti-SLP-76
(SH2 domain-containing leukocyte protein of 76) antibody
(Merck, Darmstadt, Germany); anti-Syk antibody (Wako, Osaka,
Japan); All other reagents were from previously described sources
[10].
2.2. Platelet preparation
This study was approved by the Ethical Committees in Univer-
sity of Yamanashi and informed consent was provided according to
the Declaration of Helsinki. Venous blood from healthy drug-free
volunteers was collected into 10% sodium citrate (3.8% sodium
citrate, w/v). Washed human platelets resuspended in modiﬁed
Tyrode’s buffer (137 mM NaCl, 11.9 mM NaHCO3, 0.4 mM Na2-
HPO4, 2.7 mM KCl, 1.1 mMMgCl2 and 5.6 mM glucose, pH 7.3) (2 
108/ml for aggregation study, 2  107/ml for adhesion study,
1  109/ml for immunoprecipitation) were obtained as described
elsewhere [10]. Murine blood was drawn and washed platelets
(2  108/ml) were obtained as described elsewhere [10].
2.3. Platelet aggregation
Washed platelets or platelet-rich plasma (PRP) were stimulated
with indicated concentrations of collagen, CRP, thrombin, TXA2
analogue U46619, or poly(PHG) and aggregation was monitored
by a PA-100 platelet aggregation analyzer (Kowa, Tokyo, Japan).
Where indicated, platelets were pretreated with the indicated con-
centrations of A2-IIE10, hFC2, GPVI-hFc2, DMSO, or 10 lM indo-
methacin at 37 C for 5 min. Whole blood was also stimulated by
four different concentrations of collagen, CRP or poly(PHG), and
platelet aggregation was measured by WBA-Neo according to the
manufacturer’s instructions (ISK, Tokyo, Japan). The minimumconcentration of an agonist that induces 50% aggregation was
determined as the platelet aggregation threshold index (PATI).
2.4. Adhesion assay
Cover slips were coated with several concentrations of
poly(PHG), CRP, or collagen, then blocked with BSA [11]. Washed
human platelets were seeded on the cover slips for 30 min at room
temperature. After removal of unbound platelets, adherent plate-
lets were ﬁxed, permeabilized, stained, visualized and photo-
graphed as described elsewhere [11]. Adherent platelets
(0.022 mm2/image) were counted and mean number of adhe-
sion ± S.E. per image from at least eight different images from
two separate experiments was calculated.2.5. Immunoprecipitation, pull down assay, and Western blotting
Washed platelets were pretreated with 1 mM GRGDS peptide to
inhibit the effect of platelet aggregation and then activated with
CRP or poly(PHG). Immunoprecipitation and pull down assay were
performed as described previously [10]. Brieﬂy, reactions were ter-
minated by the addition of 2 lysis buffer. The lysates were pre-
cleared with protein G-Sepharose and insoluble materials were
removed by centrifugation. A small aliquot was dissolved with
84 O. Inoue et al. / FEBS Letters 583 (2009) 81–87SDS sample buffer for detection of total tyrosine phosphorylation.
Antibodies against Syk, SLP-76, LAT, or PLCc2 plus protein G-Se-
pharose or GST-Syk-SH2 that had been coupled to glutathione-Se-
pharose were added to the resultant supernatant and incubated
overnight. The Sepharose beads were washed before addition of
SDS sample buffer. Whole-cell lysates or precipitated proteins
were separated by SDS–PAGE, electrotransferred, and Western
blotted as described previously [10]. Tyrosine-phosphorylated
FcRc-chain is observed as 10/12 kDa proteins pull-downed with
GST-Syk-SH2 [1].2.6. Surface plasmon resonance spectroscopy
A speciﬁc interaction between poly(PHG) and GPVI-hFc2 was
analyzed using a BIAcore X (BIAcore AB, Uppsala, Sweden).
Poly(PHG) was coupled to a CM5 tip (BIAcore), using Amine Cou-
pling Kit (BIAcore) and blocked as described elsewhere [11].
GPVI-hFc2 in HBS-EP buffer (BIAcore) at several concentrations
was perfused over the control surface or an immobilized
poly(PHG) surface at a ﬂow rate of 20 ll/min at 25 C, and the
resonance changes were recorded. The response from the
poly(PHG) surface was subtracted from that of the control. The
dissociation constants (Kd) were determined using BIAevaluation
software (BIAcore).NSA
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Fig. 3. Poly(PHG) induces platelet aggregation independently of TXA2 or integrin a2
indomethacin (A) or anti-integrin a2 antibody (A2-IIE10) (B) and then stimulated with c
for 5 min. The data in (A) are expressed as the means ± S.E. and analyzed with a Student’s
‘‘not signiﬁcant”. The data in (B) are the representative of three experiments from differ2.7. Statistics
The data were expressed as the means ± S.E. and analyzed with
a Student’s t-test. P-value less than 0.05 was considered statisti-
cally signiﬁcant.
3. Results
3.1.Poly(PHG) strongly stimulates platelet aggregation and increase in
protein tyrosine phosphorylation of several signaling molecules
Human washed platelets, human platelet-rich plasma (PRP), or
human whole blood were stimulated with the indicated concentra-
tions of collagen, poly(PHG), or the GPVI-speciﬁc agonist CRP.
Poly(PHG) was capable of inducing aggregation of washed platelets
(Fig. 1A) and PRP (Fig. 1B) at concentrations of as low as 1 ng/ml,
and at least 10 times more potent than CRP and 100 times more
potent than collagen. This relationship was roughly applicable for
platelet aggregation in whole blood as the minimum concentra-
tions of an agonist that induces 50% aggregation were 0.0037
lg/ml for poly(PHG), 0.049 lg/ml for CRP, and 0.21 lg/ml for col-
lagen (Fig. 1C). Poly(PHG) supported platelet adhesion in a concen-
tration-dependent manner as well as CRP and collagen (Fig. 1D).
Number of adhesion was reached to a plateau at a concentration
of 5 lg/ml in poly(PHG), 50 lg/ml in CRP, or 100 lg/ml in collagen**
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poly(PHG).
To investigate the molecular basis of platelet aggregation in-
duced by poly(PHG), we examined whether poly(PHG) stimulates
protein tyrosine phosphorylation, to which GPVI-induced platelet
activation signals are related. It is well known that cross-linking
of GPVI elicits a signal transduction cascade that involves sequen-
tial activation of Src family tyrosine kinases, phosphorylation of
FcRc-chain and Syk activation, leading to PLCc2 activation
[1,12,13]. The adapter proteins LAT and SLP-76 play a critical role
in the regulation of PLCc2 downstream of Syk [14,15]. WesternFcR  +/+
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experiments. RU: resonance units, A: 500 nM, B: 333 nM, C: 200 nM, D: 133 nM, E: 66.7blotting analysis of whole-cell lysates showed that poly(PHG) in-
duced marked increase in tyrosine phosphorylation of proteins,
the pattern of which was almost identical to that observed in
CRP-stimulated platelets (Fig. 2A). Immunoprecipitation studies
revealed that the proteins that undergo an increase in tyrosine
phosphorylation upon platelet stimulation with poly(PHG) are
invariably present in the CRP-stimulated GPVI signaling cascade,
namely FcRc-chain, the tyrosine kinase Syk, the adapter proteins
LAT and SLP-76, and PLCc2 (Fig. 2B). These ﬁndings imply that
poly(PHG) induces platelet aggregation depending on GPVI, similar
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secondary mediator TXA2 and integrin a2b1
It is well known that the GPVI agonists CRP and convulxin can
activate platelets independently of TXA2; however, responses to
collagen were dependent on the secondary mediator [1]. A major
difference between platelet activation induced by the GPVI speciﬁc
agonists and collagen is the involvement of additional receptors for
collagen in platelets, most notably the integrin a2b1 [1]. Since nat-
ural collagen is a macromolecule and the content of the Gly-Pro-
Hyp motif recognizable with GPVI is only 10% of the total weight
of collagen ﬁbers, it could not ﬁrmly bind to GPVI without the help
of a2b1. However, the content of the Gly-Pro-Hyp motif in CRP is
80%, which could ﬁrmly bind to GPVI without the help of a2b1.
Afﬁnity of a2b1 for their ligands is increased by inside-out signals
elicited by the receptors for ADP, TXA2, which promote ﬁrm plate-
let–collagen interactions, leading to enhanced signaling [1].
Platelet aggregation induced even by a supra-maximal concen-
tration of collagen (30 lg/ml) was signiﬁcantly inhibited by the
blockade of TXA2 production by indomethacin, whereas CRP- and
poly(PHG)-induced platelet aggregation was not affected by indo-
methacin (Fig. 3A), suggesting that a2b1 which requires TXA2 pro-
duction is not involved in poly(PHG)-mediated platelet activation.
Fig. 3B shows that the anti-a2 blocking antibody dose-dependently
inhibited collagen-induced platelet aggregation, but not that of
poly(PHG) (Fig. 3B), further conﬁrming that poly(PHG) stimulates
platelet aggregation independently of a2b1.
3.3. Poly(PHG) failed to induce platelet aggregation in the absence of
GPVI/FcRc-chain
To verify that poly(PHG) induces platelet aggregation depend-
ing on GPVI, we utilized murine platelets from mice lacking
GPVI/FcRc-chain. Platelet aggregation induced by CRP or
poly(PHG), but not that induced by thrombin, was completely
inhibited in the absence of GPVI/FcRc-chain complex (Fig. 4A).
Moreover, recombinant extracellular domain of GPVI fused with
human IgG Fc2 (GPVI-hFc2), but not recombinant human IgG Fc
(hFc2), completely inhibit poly(PHG)-induced platelet aggregation,
whereas both recombinant proteins did not affect a TXA2 mimetic
U46619-induced platelet aggregation (Fig. 4B). A surface plasmon
resonance spectroscopy (BIAcore) conﬁrmed direct and dose-
dependent binding of the recombinant GPVI to poly(PHG)-coated
surfaces (Fig. 4C). The Kd for the interaction of GPVI-Fc2 with
poly(PHG) was calculated as 54.5 ± 43.0 lM (means ± S.D.), that
was almost equivalent to that of GPVI-hFc2 with CRP (27.1 ±
19.0 lM) [7]. These data suggest that poly (PHG) indices platelet
aggregation solely by binding to GPVI, independently of integrin
a2b1.4. Discussion
We demonstrated that the synthetic collagen poly(PHG) stimu-
lates platelet aggregation by binding to GPVI. One of the issues to
be addressed is the difference between the GPVI-speciﬁc agonist
CRP and our poly(PHG). CRP is comprised of 10 (Gly-Pro-Hyp) mo-
tifs and either a lysyl or a cysteine residue at both ends (Gly-Lys(or
Cys)-Hyp-(Gly-Pro-Hyp)10-Gly-Lys(or Cys)-Hyp-Gly) that mimic
the tertiary (triple-helical) structure of collagen molecules [2].
Since the polymeric structure of collagen is essential for its plate-
let-stimulating activity, cross-linking via either lysyl or cysteine
residues to impart quaternary (polymeric) structure is essential
[2]. On the other hand, poly(PHG), as well as natural collagen,
spontaneously assemble into a polymeric (organized triple-helical)
structure without chemical cross-linking [5]. This may be becauseCRP consists of only ten (Gly-Pro-Hyp) motifs, which is not long
enough to physically form the polymeric structure, but poly(PHG)
has long ﬁber-like structure, which may facilitate spontaneous
polymerization. The transmission electron microscopic images of
poly(PHG) and CRP in a previous report support this notion;
poly(PHG) assumes ﬁber-like structures [5], while there are micro-
aggregates with CRP preparations [2]. Our present data demon-
strate that poly(PHG) is at least 10 times more potent than CRP
and 100 times more potent than collagen in inducing platelet acti-
vation (Fig. 1). Since the content of the Gly-Pro-Hyp motif recog-
nizable with GPVI is approximately 10% of the total weight of the
natural collagen, 80% with CRP, and 100% with poly(PHG),
poly(PHG) may be able to more effectively cluster GPVI molecules
than collagen or CRP.
CRP and convulxin are widely used as GPVI agonists to investi-
gate the GPVI-mediated activation signals in laboratory research.
We propose that poly(PHG) can serve as a better GPVI agonist than
CRP and convulxin in several aspects. It is frequently observed that
different preparations of CRP cross-linked via either lysyl or cys-
teine residues show variable abilities to induce platelet aggrega-
tion. One the other hand, since poly(PHG) spontaneously forms
polymeric structure without cross-linking, variability in its activity
induced by different levels of cross-linking could be minimized in
the case of poly(PHG). Cost-wise, CRP polypeptide is expensive, as
it consists of as long as 37 amino acids. As for convulxin, puriﬁca-
tion of convulxin from crude snake venoms requires relatively dif-
ﬁcult techniques and thus commercially-available convulxin
preparations are quite expensive. Since poly(PHG) is made by di-
rect polycondensation of Pro-Hyp-Gly tripeptides on a large scale,
the cost of poly(PHG) production is considerably less than that of
CRP or convulxin.
In clinical settings, platelet aggregation tests are performed to
evaluate bleeding disorders or to monitor the effect of anti-platelet
drugs. Animal-derived natural collagen is widely used to stimulate
platelet-rich plasma as an agonist of platelet activation. Potential
contamination of animal-derived collagen with pathogens has re-
cently created a demand for safer resources for collagen, namely
recombinant collagen, and there are several commercially-avail-
able products of recombinant human collagen. However, they are
extremely expensive. The synthetic poly(PHG) meets the demand
well, since it induces platelet aggregation and has no pathogen.
Moreover, since it can be produced in a large quantity, a large num-
ber of poly(PHG) preparations can be supplied as a uniform quality
at a relatively low cost, and thus it is most suitable to realize stan-
dardization of platelet aggregation tests with the use of the agonist
of the same potency for all the users.Acknowledgments
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